Investor Presentaiton slide image

Investor Presentaiton

Total shareholders' equity to CET1 capital Total equity to CET1 capital, at 31 December 2022, $m Total equity to CET1 capital walk, $m Strategy 4022 results Appendix 4022 Total equity Non-controlling interests Total shareholders' equity 196,028 Total equity (per balance sheet) Non-controlling interests 196,028 3022 185,993 (8,544) (8,335) 2022 196,690 (8,308) 4Q21 206,777 (8,527) (8,544) Total shareholders' equity 187,484 177,658 188,382 198,250 Additional Tier 1 (19,746) (19,746) (21,691) (22,414) 187,484 Total ordinary shareholders' equity 167,738 157,912 166,691 175,836 Foreseeable dividend (4,436) (3,926) (3,548) (3,655) Additional Tier 1 (19,746) Adjustment for insurance / SPE's *.73 (3) 4 Allowable NCI in CET1 4,444 4,272 Total ordinary shareholders' equity Foreseeable dividend insurance / SPE'S 167,738 CET1 before regulatory adjustments 167,743 158,262 (12,881) 4,392 154,654 (13,449) 4,186 162,918 Prudential valuation adjustment (1,171) (1,334) (1,299) (1,217) Intangible assets (12,141) (11,082) (11,746) (9,123) (4,436) Deferred tax asset deduction (4,235) (3,528) (3,274) (1,520) Deconsolidation of Cash flow hedge adjustment 3,601 4,669 2,124 170 (3) Excess of expected loss (1,248) (1,992) (2,373) (2,020) Allowable NCI in CET1 4,444 Own credit spread and debit valuation adjustment Defined benefit pension fund assets (412) (1,589) (778) 1,571 (5,448) (5,639) (6,638) (7,146) CET1 before 167,743 regulatory adjustments Direct and indirect holdings of CET1 instruments Other regulatory adjustments to CET1 capital (including IFRS 9 transitional adjustments when relevant) (40) (40) (40) (40) (220) (340) (235) 766 Regulatory adjustments (48,452) CET1 capital 119,291 Threshold deductions* Regulatory adjustments CET1 capital (27,138) (48,452) 119,291 (26,630) (14,615) (11,794) (47,505) (38,874) (30,353) 110,757 115,780 132,565 * These rows include offsetting entries of $12,660m for 3Q22 and $13,200m for 4Q22 relating to the start of equity accounting for our insurance subsidiaries with effect from 3Q22 53
View entire presentation